Loading...
XKRX000020
Market cap124mUSD
Jan 08, Last price  
6,520.00KRW
1D
-0.15%
1Q
-15.43%
Jan 2017
-19.70%
Name

Dongwha Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:000020 chart
P/E
6.59
P/S
0.50
EPS
989.91
Div Yield, %
2.76%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
3.33%
Revenues
361.11b
+6.08%
148,738,623,000175,119,773,000188,607,515,000145,115,173,000215,279,424,000234,561,984,470223,371,996,540220,240,574,700213,472,144,940223,201,285,430237,470,834,800258,881,616,580306,602,589,030307,150,025,790272,075,383,800293,018,112,030340,426,327,300361,108,562,000
Net income
27.44b
+34.61%
8,065,194,00021,495,381,00028,518,530,0006,717,401,0005,427,207,00017,679,223,0701,311,240,9201,011,859,7504,937,204,9605,608,652,16026,254,318,41047,009,013,18010,068,506,3809,402,231,12028,507,687,36017,870,404,58020,383,458,97027,438,289,761
CFO
29.17b
-0.19%
23,185,889,00023,655,312,00031,155,090,00029,920,326,00018,587,828,00046,244,031,85025,226,760,3608,205,110,34013,514,667,97019,833,109,34025,482,187,950-16,519,974,690-4,360,077,74013,284,966,21052,228,225,09036,031,211,87029,220,766,68029,166,607,898
Dividend
Dec 27, 2023180 KRW/sh

Profile

Dongwha Pharm Co., Ltd. manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and teeth, hepatic protector, nutrient, tonic, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company was founded in 1897 and is based in Seoul, South Korea.
URL
http://www.dong-wha.co.kr/
IPO date
Mar 24, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
361,108,562
6.08%
340,426,327
16.18%
Cost of revenue
335,806,487
255,344,830
Unusual Expense (Income)
NOPBT
25,302,075
85,081,497
NOPBT Margin
7.01%
24.99%
Operating Taxes
8,718,534
1,494,337
Tax Rate
34.46%
1.76%
NOPAT
16,583,541
83,587,160
Net income
27,438,290
34.61%
20,383,459
14.06%
Dividends
(4,982,243)
(4,982,243)
Dividend yield
1.75%
1.94%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
19,217,226
4,619,662
Long-term debt
44,187,175
5,731,162
Deferred revenue
10
22,872
Other long-term liabilities
17,126,195
2,737,521
Net debt
(98,073,220)
(80,577,135)
Cash flow
Cash from operating activities
29,166,608
29,220,767
CAPEX
(24,540,643)
(20,091,490)
Cash from investing activities
2,862,952
(43,272,030)
Cash from financing activities
5,865,503
(12,013,033)
FCF
(35,881,668)
65,040,900
Balance
Cash
88,830,180
107,694,515
Long term investments
72,647,442
(16,766,556)
Excess cash
143,422,193
73,906,642
Stockholders' equity
393,076,074
628,982,525
Invested Capital
327,861,406
308,747,218
ROIC
5.21%
28.39%
ROCE
5.29%
22.11%
EV
Common stock shares outstanding
27,686
27,679
Price
10,270.00
10.91%
9,260.00
-36.58%
Market cap
284,331,256
10.93%
256,308,744
-36.47%
EV
223,648,072
190,004,433
EBITDA
39,198,106
97,590,621
EV/EBITDA
5.71
1.95
Interest
308,010
370,004
Interest/NOPBT
1.22%
0.43%